کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2478582 | 1113379 | 2006 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Télomères et télomérase, de nouvelles cibles pour la chimiothérapie anticancéreuse
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
اکتشاف دارویی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Télomères et télomérase, de nouvelles cibles pour la chimiothérapie anticancéreuse Télomères et télomérase, de nouvelles cibles pour la chimiothérapie anticancéreuse](/preview/png/2478582.png)
چکیده انگلیسی
Telomeres are composed of single-strand DNA rich in guanine which can adopt particular structures such as T-loop or G-quadruples, a four-strand DAN structure formed by guanine repeats. Telomeric single-strand DNA is the substrate of telomerase, an enzyme necessary for telomeric replication which is suppressed in most cancer cells and which participates in tumor genesis. The formation of a telomeric Gquadruplex blocks telomerase activity and offers an original strategy for new anti-cancer agents. Using an original approach combining rational screening and synthesis, several series of compounds have been identified which specifically bind to the telomeric quadruplex. These derivatives, called “Gquadruplex DNA ligands”, are able to block telomeric replication in cancer cells and provoke replicative senescence and/or apoptosis after a few cell cycles. Our team is working on characterizing the cellular and molecular mechanisms of action of these ligands. Using mutant cell models resistant to these ligands or expressing a protein cuff covering the telomere in tumor lines, we have demonstrated that the telomere is the principal intracellular target of action of these compounds and the implicit existence of the G-quadruplex structure. In collaboration with academic and industrial partners, optimization of these ligands to develop pharmacologically active products should enable in vivo validation of a new thereapeutic concept.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Annales Pharmaceutiques Françaises - Volume 64, Issue 2, February 2006, Pages 97-105
Journal: Annales Pharmaceutiques Françaises - Volume 64, Issue 2, February 2006, Pages 97-105
نویسندگان
J.-F. Riou, H. Morjani, C. Trentesaux,